Cargando…
Salvage Using Polatuzumab Vedotin Based Therapy in Relapsed Refractory Large B-Cell Lymphomas: Early Experience from a Real-World Middle-Income Setting Using Named-Patient Compassionate Access Program
Polatuzumab vedotin is a novel immunotherapy antibody–drug conjugate targeting CD79b. It has been used in relapsed/refractory (R/R) large B-cell lymphomas since its FDA approval in 2019. Presently, this drug is unaffordable or unavailable for patients in Lower–Middle Income Countries (LMIC) like Ind...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer India
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790077/ https://www.ncbi.nlm.nih.gov/pubmed/36590655 http://dx.doi.org/10.1007/s12288-022-01619-w |
_version_ | 1784859093483126784 |
---|---|
author | Radhakrishnan, V. S. Pincha, R. Raina, V. Garg, J. K. Nag, A. Bhave, S. J. Achari, R. Dey, D. Arun, I. Lateef, Z. Vinarkar, S. S. Parihar, M. Sen, S. Mishra, D. K. Chandy, M. Nair, R. |
author_facet | Radhakrishnan, V. S. Pincha, R. Raina, V. Garg, J. K. Nag, A. Bhave, S. J. Achari, R. Dey, D. Arun, I. Lateef, Z. Vinarkar, S. S. Parihar, M. Sen, S. Mishra, D. K. Chandy, M. Nair, R. |
author_sort | Radhakrishnan, V. S. |
collection | PubMed |
description | Polatuzumab vedotin is a novel immunotherapy antibody–drug conjugate targeting CD79b. It has been used in relapsed/refractory (R/R) large B-cell lymphomas since its FDA approval in 2019. Presently, this drug is unaffordable or unavailable for patients in Lower–Middle Income Countries (LMIC) like India. This is a retrospective study of adult (> 18 years) patients with R/R large B-cell lymphoma failing two prior lines of therapy, who received Polatuzumab based salvage therapy on a compassionate or named-patient access program. Between May 2019 and April 2022, 10 patients received Polatuzumab vedotin, and 9 were evaluable. The most common regimen used was Polatuzumab-Bendamustine-Rituximab. Out of 43 infusions administered, the adverse event profile was manageable [One grade-2 infusion reaction, 4 patients developed grade 3–4 hematological toxicity and none had grade 3–4 non-hematological toxicities]. Ten infusions were administered in the day care service. After a median of 4.5 cycles (range 1–8), 4 patients achieved CR, 2 had partial response (PR), and 3 had progressive disease (PD). With a median follow up of 491 days (range 8–1048 days), four patients are alive (three in CR and one in PR), three patients have died and three patients were lost to follow up. Early real-world experience from a LMIC setting demonstrates feasibility and a favourable safety profile of Polatuzumab vedotin based approach, along with encouraging response rates in a subset of patients. |
format | Online Article Text |
id | pubmed-9790077 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer India |
record_format | MEDLINE/PubMed |
spelling | pubmed-97900772022-12-27 Salvage Using Polatuzumab Vedotin Based Therapy in Relapsed Refractory Large B-Cell Lymphomas: Early Experience from a Real-World Middle-Income Setting Using Named-Patient Compassionate Access Program Radhakrishnan, V. S. Pincha, R. Raina, V. Garg, J. K. Nag, A. Bhave, S. J. Achari, R. Dey, D. Arun, I. Lateef, Z. Vinarkar, S. S. Parihar, M. Sen, S. Mishra, D. K. Chandy, M. Nair, R. Indian J Hematol Blood Transfus Short Communication Polatuzumab vedotin is a novel immunotherapy antibody–drug conjugate targeting CD79b. It has been used in relapsed/refractory (R/R) large B-cell lymphomas since its FDA approval in 2019. Presently, this drug is unaffordable or unavailable for patients in Lower–Middle Income Countries (LMIC) like India. This is a retrospective study of adult (> 18 years) patients with R/R large B-cell lymphoma failing two prior lines of therapy, who received Polatuzumab based salvage therapy on a compassionate or named-patient access program. Between May 2019 and April 2022, 10 patients received Polatuzumab vedotin, and 9 were evaluable. The most common regimen used was Polatuzumab-Bendamustine-Rituximab. Out of 43 infusions administered, the adverse event profile was manageable [One grade-2 infusion reaction, 4 patients developed grade 3–4 hematological toxicity and none had grade 3–4 non-hematological toxicities]. Ten infusions were administered in the day care service. After a median of 4.5 cycles (range 1–8), 4 patients achieved CR, 2 had partial response (PR), and 3 had progressive disease (PD). With a median follow up of 491 days (range 8–1048 days), four patients are alive (three in CR and one in PR), three patients have died and three patients were lost to follow up. Early real-world experience from a LMIC setting demonstrates feasibility and a favourable safety profile of Polatuzumab vedotin based approach, along with encouraging response rates in a subset of patients. Springer India 2022-12-25 2023-10 /pmc/articles/PMC9790077/ /pubmed/36590655 http://dx.doi.org/10.1007/s12288-022-01619-w Text en © The Author(s), under exclusive licence to Indian Society of Hematology and Blood Transfusion 2022 |
spellingShingle | Short Communication Radhakrishnan, V. S. Pincha, R. Raina, V. Garg, J. K. Nag, A. Bhave, S. J. Achari, R. Dey, D. Arun, I. Lateef, Z. Vinarkar, S. S. Parihar, M. Sen, S. Mishra, D. K. Chandy, M. Nair, R. Salvage Using Polatuzumab Vedotin Based Therapy in Relapsed Refractory Large B-Cell Lymphomas: Early Experience from a Real-World Middle-Income Setting Using Named-Patient Compassionate Access Program |
title | Salvage Using Polatuzumab Vedotin Based Therapy in Relapsed Refractory Large B-Cell Lymphomas: Early Experience from a Real-World Middle-Income Setting Using Named-Patient Compassionate Access Program |
title_full | Salvage Using Polatuzumab Vedotin Based Therapy in Relapsed Refractory Large B-Cell Lymphomas: Early Experience from a Real-World Middle-Income Setting Using Named-Patient Compassionate Access Program |
title_fullStr | Salvage Using Polatuzumab Vedotin Based Therapy in Relapsed Refractory Large B-Cell Lymphomas: Early Experience from a Real-World Middle-Income Setting Using Named-Patient Compassionate Access Program |
title_full_unstemmed | Salvage Using Polatuzumab Vedotin Based Therapy in Relapsed Refractory Large B-Cell Lymphomas: Early Experience from a Real-World Middle-Income Setting Using Named-Patient Compassionate Access Program |
title_short | Salvage Using Polatuzumab Vedotin Based Therapy in Relapsed Refractory Large B-Cell Lymphomas: Early Experience from a Real-World Middle-Income Setting Using Named-Patient Compassionate Access Program |
title_sort | salvage using polatuzumab vedotin based therapy in relapsed refractory large b-cell lymphomas: early experience from a real-world middle-income setting using named-patient compassionate access program |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790077/ https://www.ncbi.nlm.nih.gov/pubmed/36590655 http://dx.doi.org/10.1007/s12288-022-01619-w |
work_keys_str_mv | AT radhakrishnanvs salvageusingpolatuzumabvedotinbasedtherapyinrelapsedrefractorylargebcelllymphomasearlyexperiencefromarealworldmiddleincomesettingusingnamedpatientcompassionateaccessprogram AT pinchar salvageusingpolatuzumabvedotinbasedtherapyinrelapsedrefractorylargebcelllymphomasearlyexperiencefromarealworldmiddleincomesettingusingnamedpatientcompassionateaccessprogram AT rainav salvageusingpolatuzumabvedotinbasedtherapyinrelapsedrefractorylargebcelllymphomasearlyexperiencefromarealworldmiddleincomesettingusingnamedpatientcompassionateaccessprogram AT gargjk salvageusingpolatuzumabvedotinbasedtherapyinrelapsedrefractorylargebcelllymphomasearlyexperiencefromarealworldmiddleincomesettingusingnamedpatientcompassionateaccessprogram AT naga salvageusingpolatuzumabvedotinbasedtherapyinrelapsedrefractorylargebcelllymphomasearlyexperiencefromarealworldmiddleincomesettingusingnamedpatientcompassionateaccessprogram AT bhavesj salvageusingpolatuzumabvedotinbasedtherapyinrelapsedrefractorylargebcelllymphomasearlyexperiencefromarealworldmiddleincomesettingusingnamedpatientcompassionateaccessprogram AT acharir salvageusingpolatuzumabvedotinbasedtherapyinrelapsedrefractorylargebcelllymphomasearlyexperiencefromarealworldmiddleincomesettingusingnamedpatientcompassionateaccessprogram AT deyd salvageusingpolatuzumabvedotinbasedtherapyinrelapsedrefractorylargebcelllymphomasearlyexperiencefromarealworldmiddleincomesettingusingnamedpatientcompassionateaccessprogram AT aruni salvageusingpolatuzumabvedotinbasedtherapyinrelapsedrefractorylargebcelllymphomasearlyexperiencefromarealworldmiddleincomesettingusingnamedpatientcompassionateaccessprogram AT lateefz salvageusingpolatuzumabvedotinbasedtherapyinrelapsedrefractorylargebcelllymphomasearlyexperiencefromarealworldmiddleincomesettingusingnamedpatientcompassionateaccessprogram AT vinarkarss salvageusingpolatuzumabvedotinbasedtherapyinrelapsedrefractorylargebcelllymphomasearlyexperiencefromarealworldmiddleincomesettingusingnamedpatientcompassionateaccessprogram AT pariharm salvageusingpolatuzumabvedotinbasedtherapyinrelapsedrefractorylargebcelllymphomasearlyexperiencefromarealworldmiddleincomesettingusingnamedpatientcompassionateaccessprogram AT sens salvageusingpolatuzumabvedotinbasedtherapyinrelapsedrefractorylargebcelllymphomasearlyexperiencefromarealworldmiddleincomesettingusingnamedpatientcompassionateaccessprogram AT mishradk salvageusingpolatuzumabvedotinbasedtherapyinrelapsedrefractorylargebcelllymphomasearlyexperiencefromarealworldmiddleincomesettingusingnamedpatientcompassionateaccessprogram AT chandym salvageusingpolatuzumabvedotinbasedtherapyinrelapsedrefractorylargebcelllymphomasearlyexperiencefromarealworldmiddleincomesettingusingnamedpatientcompassionateaccessprogram AT nairr salvageusingpolatuzumabvedotinbasedtherapyinrelapsedrefractorylargebcelllymphomasearlyexperiencefromarealworldmiddleincomesettingusingnamedpatientcompassionateaccessprogram |